HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.

Abstract
Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) is one of approximately 50 known lysosomal storage disorders. MPS VI is characterized by an absence or deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) resulting in accumulation of dermatan sulfate. Prior to the availability of enzyme replacement therapy (ERT), the clinical management of MPS VI was limited to supportive care and allogeneic hematopoietic stem cell transplantation (HSCT); however, due to the rarity of this disease, little is known about the long-term outcomes of HSCT for MPS VI. The following retrospective study was performed using aggregate data gathered by the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1982 and 2007 to determine survival probability for patients with MPS VI following allogeneic HSCT. This analysis identified 45 MPS VI patients with a median age of 5 years (range, 1-22 years) at the time they received an allogeneic HSCT. Cumulative incidence (95% CI) of acute graft-vs.-host disease at 100 days was 36% (21-53%). Probability of survival was 78% (65-89%) at 100 days and 66% (52-79%) at 1 and 3 years. While these data are based upon small numbers of recipients, they represent the largest series to date and may help clinicians assess the relative risks and benefits of currently available therapies.
AuthorsSean Turbeville, Helen Nicely, J Douglas Rizzo, Tanya L Pedersen, Paul J Orchard, Mitchell E Horwitz, Edwin M Horwitz, Paul Veys, Carmem Bonfim, Amal Al-Seraihy
JournalMolecular genetics and metabolism (Mol Genet Metab) Vol. 102 Issue 2 Pg. 111-5 (Feb 2011) ISSN: 1096-7206 [Electronic] United States
PMID20980181 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright © 2010 Elsevier Inc. All rights reserved.
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Graft vs Host Disease (epidemiology, etiology)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Incidence
  • Infant
  • Male
  • Mucopolysaccharidosis VI (complications, mortality, therapy)
  • Neutrophils (cytology)
  • Retrospective Studies
  • Survival Analysis
  • Transplantation, Homologous
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: